Pharmaxis finishes Phase III dosing
02 April, 2009 by Kate McDonaldClinical milestone achieved in cystic fibrosis Phase III trial
Polartechnics in merger talks
02 April, 2009 by Kate McDonaldPolartechnics in talks to merge with secret suitor
Australian biotech market today 02.04.09
02 April, 2009 by Kate McDonaldPharmaxis, Mesoblast, CathRx, Fluorotechnics, Sonic, Avita, Biota
Speeding up clinical trials
02 April, 2009 by Staff WritersEvado releases clinical trials data collection service
Australian biotech market today 31.03.09
31 March, 2009 by Kate McDonaldPharmaxis, Cochlear, CSL, HeartWare, Sirtex, Progen
Cane toads the meat in the ant’s sandwich
31 March, 2009 by Kate McDonaldTeam Bufo may have found cane toad’s Achilles heel – meat ants
Australian biotech market today 30.03.09
30 March, 2009 by Staff WritersProgen, Cytopia, Avexa, Acrux, Biota, Cellestis
ChemGenex scores high on leukaemic stem cells
30 March, 2009 by Kate McDonaldChemGenex’ lead candidate kills cancer stem cells in animal model
Patent echoes for Viralytics
30 March, 2009 by Kate McDonaldViralytics granted patent in US for oncolytic echoviruses
TGR’s Crouch wins BioBusiness award
30 March, 2009 by Kate McDonaldTGR BioSciences CSO Michael Crouch wins Advancing BioBusiness Award
Biota partner to market
30 March, 2009 by Kate McDonaldBiota’s partner Daiichi Sankyo applies for marketing licence, finishes Phase III enrolment
Australian biotech market today 26.03.09
26 March, 2009 by Staff WritersCochlear, CSL, Progen, Genera Biosystems, Peplin
Better red than dead
20 March, 2009 by Kate McDonaldFemale finches bias the gender of offspring depending on head colour
Australian biotech market today 19.03.09
19 March, 2009 by Staff WritersCSL, Cochlear, Resmed, Genera, Starpharma, Novogen
Alchemia collaborates on SK1
19 March, 2009 by Kate McDonaldAlchemia in deal with private firm SDP for sphingosine kinase 1 target
